• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Thoratec buys medical business of Levitronix in deal worth $150 million

Thoratec buys medical business of Levitronix in deal worth $150 million

August 3, 2011 By MassDevice staff

Thoratec

Thoratec Corp. (NSDQ:THOR) said it will buy the medical business of Levitronix, LLC in a deal potentially worth $150 million.

The Waltham, Mass.-based Levitronix makes magnetically levitated bearing-free motors for blood pumps and ultra-pure fluid handling.

The deal calls for the Pleasanton, Calif.-based Thoratec to fork over an up front cash payment of $110 million, with an additional $40 million in potential earnouts, according to regulatory documents filed with the federal securities and exchange commission. The deal doesn’t include Levitronix’s fluid handling business, which will continue to sell pumps and flowmeters under the Levitronix name.

“This transaction solidifies Thoratec’s position as the leading, full-line provider of mechanical circulatory support products for both acute and chronic needs, advancing the company’s mission of delivering superior therapies to a broad population of heart failure patients,” officials said in a prepared release.

The two companies are quite familiar with each other as Levitronix makes several products used by Thoratec. Levitronix makes the blood pump used in Thoratec’s HeartMate II and HeartMate III ventricular assist devices.

In 2010, Levitronix CEO Kurt Dasse told MassDevice that he co-founded the company in 2001 with legendary entrepreneur George Hatsopoulos, founder and former CEO of Thermo Electron Corp., which is now Thermo Fisher Scientific Inc. (NYSE:TMO).

He described to us the theory behind the company:

“Your heart is beating about 40 million times a year, and therefore this blood pump would have to either flex or cycle these components 40 million times a year without having any access to lubrication or being able to salvage those components,” he told us. “At some point they’re going to fail, so our goal was to design a pump that would have none of these failure components; no valves, no diaphragms, no bearings, no shafts, no seals, nothing that would wear out. That’s precisely the technology that we ultimately developed, a bearingless motor where the rotating component of the pump is magnetically levitated.”

Read our 2010 interview with Levitronix co-founder Kurt Dasse

Thoratec president & CEO Gary Burbach said the deal provides the company with “full global rights to CentriMag, the cornerstone of our acute surgical product offering, and it broadens our offering to include pediatric mechanical circulatory support through the PediMag/PediVAS product line,” he said in a prepared release.”Additionally, this transaction brings in-house significant intellectual property and expertise in full magnetic levitation, one of the core technological elements of HeartMate III as well as other potential product development opportunities in circulatory and respiratory assist.”

Filed Under: Mergers & Acquisitions, News Well, Structural Heart, Wall Street Beat Tagged With: Levitronix, Thermo Fisher Scientific, Thoratec Corp.

More recent news

  • Massachusetts Life Sciences Center offers grants to lower medtech commercial risk
  • The 10 largest medical device companies
  • CSL to drop Terumo for Haemonetics in US plasma collection supply deal
  • How 5 medtech CEOs design for access
  • Butterfly Network to chase ultrasound brain-computer interfaces with newcomer Bridge Neurotech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy